PixarBio Corp. To Establish Medical Research Center-Corporate Headquarters In Medford, Massachusetts
12/13/2013
Located in close proximity to its innovation roots at Harvard and MIT, PixarBio Corp. said it will have capacity to quickly expand beyond biomaterials needed for Parkinson’s disease to include biomaterials for Epilepsy.
“We are building a home for our world renowned and award winning team of researchers to drive innovation and accelerate the development of new treatment options for Parkinson’s disease. We’re confident that our optimized R&D model will generate key intellectual property permitting PixarBio to lead the development of next generation biomaterials for the treatment of Parkinson’s disease as well as a range of chronic neurological conditions,” says CTO Randy Holmes-Farley, PhD.
Frank Reynolds, PixarBio’s CEO adds, “We’ll move to Medford, MA in early 2014 and get to work on achieving our objective of rapidly bringing a new Parkinson’s treatment to market. Along the way we’ll explore M&A in the biomaterials space while focusing on expanding our platform.”
Project Announcements
ACG Plans Conyers, Georgia, Manufacturing Operations
10/30/2025
AlphaGraphics KC Expands Kansas City, Missouri, Operations
10/30/2025
Merck & Co. Expands Elkton, Virginia, Manufacturing Operations
10/28/2025
Tate Plans Glasgow, Kentucky, Manufacturing Operations
10/28/2025
Electrolux Consumer Products Expands Kinston, North Carolina, Manufacturing Operations
10/28/2025
Canada-Based MST Rebar Plans Bladenboro, North Carolina, Manufacturing Operations
10/28/2025
Most Read
-
2025’s Top States for Business: How the Winners Are Outpacing the Rest
Q3 2025
-
The Compliance Reckoning Is Here
Q3 2025
-
Around the Horn: Data Center Supply Chains — What's Next?
Q3 2025
-
How Consumer Trends Are Reshaping Food Facilities
Q3 2025
-
Powering the Next Generation of Projects
Q3 2025
-
First Person: Filter King’s Expansion Playbook
Q3 2025
-
Rethinking Auto Site Strategy in the Age of Tariffs and Powertrain Shifts
Q3 2025